NewAmsterdam Pharma Company N.V. (NAMS) Reports Q3 Loss, Lags Revenue Estimates

Core Insights - NewAmsterdam Pharma Company N.V. reported a quarterly loss of $0.41 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.38, and a significant increase from a loss of $0.18 per share a year ago [1] - The company's revenues for the quarter ended September 2025 were $0.35 million, missing the Zacks Consensus Estimate by 91.03%, and a sharp decline from $29.11 million in the same quarter last year [2] - The stock has increased approximately 42.1% since the beginning of the year, outperforming the S&P 500's gain of 15.1% [3] Earnings Outlook - The company's earnings outlook is crucial for investors, as it includes current consensus earnings expectations for upcoming quarters and any recent changes to these expectations [4] - The current consensus EPS estimate for the next quarter is -$0.40 on revenues of $9.96 million, and for the current fiscal year, it is -$1.30 on revenues of $27.64 million [7] Industry Context - The Medical - Drugs industry, to which NewAmsterdam Pharma belongs, is currently ranked in the top 40% of over 250 Zacks industries, indicating a favorable outlook compared to the bottom 50% [8] - Empirical research suggests a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked by investors or through tools like the Zacks Rank [5][6]